CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »

Positive data reported for eptinezumab in Sunrise trial New insights on treatment holidays with erenumab Dual CGRP ligand mAb and gepant therapy reduces headache severity CGRP-mAb switching yields migraine day reduction Lower switching rates with atogepant than CGRP mAbs EMBRACE shows erenumab reduces migraine severity Older patients benefit from CGRP mAbs too DELIVER shows long term QoL benefits with eptinezumab

Dr Jonathan Jia Yuan Ong

Editorial Board

Consultant and Clinical Director, Division of Neurology, National University Health System, Singapore

Jonathan Jia Yuan Ong is a Consultant and Clinical Director within the Division of Neurology, National University Health System, Singapore. He is also a Clinician Educator with Yong Loo Lin School of Medicine, National University of Singapore, and President of the Headache Society of Singapore.

Dr Ong graduated from the Faculty of Medicine, National University of Singapore, in 2007. He has been a member of the Royal College of Physicians (UK) since 2011 and obtained his Master of Medicine (Internal Medicine) (Singapore) in 2012. He received his specialist accreditation in Neurology in 2014. He has been a Fellow of the Royal College of Physicians (Edinburgh) since 2015.

Apart from seeing patients with a variety of neurological conditions, Dr Ong’s main interest lies in headache disorders and facial pain. He was awarded the Academic Medicine Development Award 2016/2017 for a Fellowship in Headache Neurology at King’s College Hospital, London, under the tutelage of Professor Peter J Goadsby. He is the clinical lead for Headache Disorders at National University Hospital and Ng Teng Fong General Hospital.

« Back to Editorial Board

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |